Document is current

Article History

Received: 15 November 2024

Accepted: 4 March 2025

First Online: 8 May 2025

Competing interests

: N.L.A. has received honoraria for lectures, consultation or advisory board participation from Novartis, Advanced Accelerator Applications, ABX, Telix Pharmaceuticals, OncLive, MEDSIR and Servier and research funding from Novocure and Telix Pharmaceuticals. N.G. received honoraria for lectures from Blue Earth Diagnostics, for advisory board participation from Telix Pharmaceuticals and Servier and for consultancy services from Telix Pharmaceuticals. B.M.E. reports research funding from Siemens, honoraria for consultancy and/or advisory or data monitoring board participation from Alpheus Medical, Carthera, Chimerix, Ellipses Pharma, Erasca, the Global Coalition for Adaptive Research, Imaging Endpoints, Medicenna, Voiant, Medscape, Monteris, Neosoma, Nerviano Medical Sciences, Orbus Therapeutics, Sagimet Biosciences, Sapience Therapeutics, Servier Pharmaceuticals, SonALAsense, Sunitomo Dainippon Pharma Oncology, Telix, Third Rock Ventures and the NIH/NCI Cancer Imaging Steering Committee. M.J.v.d.B. has received research support from Boehringer Ingelheim, honoraria for consultancy to or participation in advisory boards from Servier, AnHeart Therapeutics, Boehringer Ingelheim, Fore Biotherapeutics, Genenta, Incyte, Chimerix, Alexion and SymBio Pharma and support for travel from Servier. S.M.C. has no COI to disclose. F.C. has no COI to disclose. E.-S.K. has received honoraria for advisory board participation from Telix and Servier. I.L. has received honoraria for lectures and consultation from Telix Pharmaceuticals and Ribocure. E.L.R. has received research grants from Bristol Myers Squibb and honoraria for lectures or advisory board participation or consulting from Bayer, Biodexa/Sitoxi, Janssen, LEO Pharma, Pierre Fabre, Roche, Seattle Genetics and Servier. M.J.M. has received research funding from Bristol Myers Squibb and travel support from Pierre Fabre. J.-M.W. has no COI to disclose. A.S.B. has research support from Daiichi Sankyo and Roche and honoraria for lectures, consultation or advisory board participation from Roche, Bristol Myers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa, Seagen, Alexion and Servier as well as travel support from Roche, Amgen and AbbVie. J.F. has received honoraria for lectures, consultation or advisory board participation from Novartis, Seagen, Sanova and Servier. G.M. has received honoraria from lectures, consultation or advisory board participation from Brainlab, Accuray, Servier, Novocure and AstraZeneca. A.M.S. reports trial funding from EMD Serono, ITM, Telix Pharmaceuticals, Avid Radiopharmaceuticals, Fusion Pharmaceuticals and Cyclotek (funds paid to institution), research funding from MedImmune, Avid Radiopharmaceuticals, AdAlta, Antengene, Humanigen, Telix Pharmaceuticals and Theramyc (funds paid to institution) and advisory board participation for Telix, Imagion and ImmunOs. S.C.S. has received research grant support from Blue Earth Diagnostics, CeCaVa and Apollomics and consultation or advisory board participation from Roche, Tocagen, Servier, Miltenyi, Medac and Chimerix. J.I. is a principal investigator on investigator-initiated trial grants from Novartis Pharmaceuticals, General Electric Healthcare and Curium Pharma (funds paid to institution). J.I. has received conference travel support from Siemens Healthineers. D.R.J. has received honoraria for consultation or advisory board participation from Novartis, Telix Pharmaceuticals and Cellectar Biosciences. B.S. has received honoraria for lectures and consultation from Novocure. N.T. has received honoraria for advisory board participation from Telix Pharmaceuticals and receives in-kind funding from Curium Pharma. A.V. has received honoraria for lectures and advisory board participation from Curium, Eisai, General Electric and Novartis. J.-C.T. has received reimbursement of travel expenses from Servier. E.G. has received compensation for advisory board participation from Kiyatec, Karyopharm Therapeutics, Boston Scientific, Servier Pharmaceuticals, Boehringer Ingelheim and Modifi Biosciences and research funding from Servier Pharmaceuticals (formerly Agios Pharmaceuticals) and Denovo Biopharma. P.K.B. has consulted for ElevateBio, Genentech, Angiochem, Tesaro, Axiom Healthcare Strategies, InCephalo Therapeutics, Medscape, MPM Capital Advisors, Dantari Pharmaceuticals, SK Life Science, Pfizer, CraniUS, Eli Lilly, Kazia, Sintetica, Voyager Therapeutics, Advise Connect Inspire, Merck and Atavistik, is on the scientific advisory board for CraniUS and Kazia and has received speaker’s honoraria from Genentech and Pfizer and research support (institution) from Merck, Mirati, Eli Lilly and Kinnate. P.Y.W. has received research support from AstraZeneca, Black Diamond, Bristol Myers Squibb, Chimerix, Eli Lilly, Erasca, the Global Coalition for Adaptive Research, Kazia, MediciNova, Merck, Novartis, Quadriga, Servier and VBI Vaccines and honoraria for advisory board participation or consulting from AstraZeneca, Black Diamond, Bristol Myers Squibb, Chimerix, Eli Lilly, Erasca, the Global Coalition for Adaptive Research, Kazia, MediciNova, Merck, Novartis, Quadriga, Servier and VBI Vaccines. M.W. has received research grants from Novartis, Quercis and Versameb and honoraria for lectures or advisory board participation or consulting from AnHeart, Bayer, CureVac, Medac, NeuroSense, Novartis, Novocure, Orbus, Pfizer, Philogen, Roche and Servier. N.U.L. reports institutional research support from Genentech (and Zion Pharmaceutical as part of GNE), Pfizer, Merck, Seattle Genetics (now Pfizer), Olema Pharmaceuticals and AstraZeneca, consulting honoraria from Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera and Eisai, royalties from UpToDate and travel support from Olema Pharmaceuticals and AstraZeneca. M.P. has received honoraria for lectures, consultation or advisory board participation from Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, MedAhead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals and Servier as well as travel support from Servier, Daiichi Sankyo, Roche and MEDSIR.